These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16207114)

  • 21. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma.
    Marc MM; Korosec P; Kosnik M; Kern I; Flezar M; Suskovic S; Sorli J
    Am J Respir Cell Mol Biol; 2004 Aug; 31(2):216-9. PubMed ID: 15039137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on the relation between concentration of circulating non-host fetal DNA in pregnant women and pre-eclampsia].
    Tao H; Wang XM; Ji XH
    Zhonghua Fu Chan Ke Za Zhi; 2005 Dec; 40(12):808-11. PubMed ID: 16412324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
    Erez O; Gotsch F; Mazaki-Tovi S; Vaisbuch E; Kusanovic JP; Kim CJ; Chaiworapongsa T; Hoppensteadt D; Fareed J; Than NG; Nhan-Chang CL; Yeo L; Pacora P; Mazor M; Hassan SS; Mittal P; Romero R
    J Matern Fetal Neonatal Med; 2009 Aug; 22(8):672-87. PubMed ID: 19736615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement split products c3a and c4a in chronic lyme disease.
    Stricker RB; Savely VR; Motanya NC; Giclas PC
    Scand J Immunol; 2009 Jan; 69(1):64-9. PubMed ID: 19140878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement inhibition keeps mothers calm and avoids fetal rejection.
    Girardi G
    Immunol Invest; 2008; 37(5):645-59. PubMed ID: 18716942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction.
    Cetin I; Cozzi V; Pasqualini F; Nebuloni M; Garlanda C; Vago L; Pardi G; Mantovani A
    Am J Obstet Gynecol; 2006 May; 194(5):1347-53. PubMed ID: 16647920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in plasma complement levels after human ischemic stroke.
    Mocco J; Wilson DA; Komotar RJ; Sughrue ME; Coates K; Sacco RL; Elkind MS; Connolly ES
    Neurosurgery; 2006 Jul; 59(1):28-33; discussion 28-33. PubMed ID: 16823297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acidosis activates complement system in vitro.
    Emeis M; Sonntag J; Willam C; Strauss E; Walka MM; Obladen M
    Mediators Inflamm; 1998; 7(6):417-20. PubMed ID: 9927235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
    Germin Petrović D
    Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.
    Soto E; Romero R; Richani K; Espinoza J; Chaiworapongsa T; Nien JK; Edwin SS; Kim YM; Hong JS; Goncalves LF; Yeo L; Mazor M; Hassan SS; Kusanovic JP
    J Matern Fetal Neonatal Med; 2010 Jul; 23(7):646-57. PubMed ID: 19900030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.
    Girardi G; Redecha P; Salmon JE
    Nat Med; 2004 Nov; 10(11):1222-6. PubMed ID: 15489858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity.
    Samarkos M; Mylona E; Kapsimali V
    Semin Arthritis Rheum; 2012 Aug; 42(1):66-9. PubMed ID: 22405029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome.
    Bauer M; Hutterer G; Eder M; Majer S; Leshane E; Johnson KL; Peter I; Bianchi DW; Pertl B
    Prenat Diagn; 2006 Sep; 26(9):831-6. PubMed ID: 16832830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolytic treatment and complement activation.
    Agostoni A; Gardinali M; Frangi D; Cugno M; Cafaro C; Conciato L; Sponzilli C; Salmoirago E
    Ann Ital Med Int; 1994; 9(3):178-9. PubMed ID: 7946896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Third trimester nonrecurrent fetal loss is associated with factor V Leiden and prothrombin gene mutations.
    Karateke A; Haliloglu B; Gurbuz A
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):299-304. PubMed ID: 16390788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum complement levels and severity of sepsis.
    Nakae H; Endo S; Inada K; Takakuwa T; Kasai T; Yoshida M
    Res Commun Chem Pathol Pharmacol; 1994 May; 84(2):189-95. PubMed ID: 8091004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the complement anaphylatoxins in the recruitment of eosinophils.
    DiScipio RG; Schraufstatter IU
    Int Immunopharmacol; 2007 Dec; 7(14):1909-23. PubMed ID: 18039528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.
    Lillegard KE; Loeks-Johnson AC; Opacich JW; Peterson JM; Bauer AJ; Elmquist BJ; Regal RR; Gilbert JS; Regal JF
    J Pharmacol Exp Ther; 2014 Nov; 351(2):344-51. PubMed ID: 25150279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement levels and exposure in the hypobaric chamber.
    Brook WH; Secombe J; Seychell D
    Aviat Space Environ Med; 1995 May; 66(5):415-7. PubMed ID: 7619033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunological tests: Anaphylatoxins C3a, C4a, C5a].
    Fujino S; Sakurabayashi I
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():80-3. PubMed ID: 16111194
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.